Fig. 1
Distinctive expression of ELF2 isoforms in normal tissues. a ELF2 genomic locus indicating isoforms arising from alternative promoters: P1 and P2 (ELF2A) and P3 (ELF2B). Coding exons unique to ELF2A (red shading) and ELF2B (blue shading), common exons (black shading) and untranslated regions (no shading). Putative enhancer sequences in ELF2B (+0.5, +1.5, +8.2) indicate distance (in kb) from the transcription start site in P3. Transcription factor binding sites predicted (black) and experimentally validated (red) are indicated. b RT-qPCR analysis of Elf2a and Elf2b isoforms in mouse tissues normalised to β-actin expression. c RNAseq analysis of Elf2 isoforms arising from alternate promoters in mouse tissues: Pro promyelocytes, Gr granulocytes; B B cells, T T cells, ES embryonic stem cells. Expression level of isoforms arising from each promoter is given in FPKM (fragments per kilobase of transcript per million mapped reads). d Schematic of ELF2 protein isoforms: shading indicates domains unique to ELF2A (red) or ELF2B (blue) and the common Ets DNA-binding domain (grey) and putative bipartite NLS (ELF2A aa 160-190; ELF2B aa 100-130; black). A similarity plot of 20 orthologues (human to zebrafish) and PONDR analysis of protein disorder are shown below. e Western blot confirming the subcellular localisation of ELF2a in mouse A20 and CH12 B cell lines: C cytoplasmic, N nuclear lysates. GAPDH and Lamin B1 are positive controls for cytoplasmic and nuclear loading, respectively. Immunising peptide was used to pre-block antibodies where indicated. f Western blot of Elf2a and Elf2b expression in mouse tissues